354 related articles for article (PubMed ID: 33121439)
1. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
4. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
[TBL] [Abstract][Full Text] [Related]
5. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
[TBL] [Abstract][Full Text] [Related]
9. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
10. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
11. How to use virological tools for the optimal management of chronic hepatitis C.
de Leuw P; Sarrazin C; Zeuzem S
Liver Int; 2011 Jan; 31 Suppl 1():3-12. PubMed ID: 21205131
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
[TBL] [Abstract][Full Text] [Related]
15. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Performance of Algorithms That Use Serial Hepatitis C RNA Tests to Predict Treatment Initiation and Sustained Virological Response Among Patients Infected With Hepatitis C Virus.
Osinubi A; Harris AM; Vellozzi C; Lom J; Miller L; Millman AJ
Am J Epidemiol; 2019 Mar; 188(3):555-561. PubMed ID: 30535062
[TBL] [Abstract][Full Text] [Related]
19. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson AJ; Levy M; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
Dig Dis Sci; 2023 Jan; 68(1):291-303. PubMed ID: 35552941
[TBL] [Abstract][Full Text] [Related]
20. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
